Загрузка...
Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
The major mechanism of imatinib (IM) resistance of CML is the reactivation of ABL kinase either through BCR‐ABL gene amplification or mutation. We investigated the cytotoxicity of a pan‐ABL tyrosine kinase inhibitor, ponatinib, and a pan‐histone deacetylase inhibitor, panobinostat, against IM‐resist...
Сохранить в:
| Опубликовано в: : | Cancer Sci |
|---|---|
| Главные авторы: | , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4946706/ https://ncbi.nlm.nih.gov/pubmed/27166836 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12965 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|